Houlihan Lokey Advises Fujirebio Holdings
Houlihan Lokey is pleased to announce that Fujirebio Holdings, Inc. (Fujirebio) has acquired Plasma Services Group, Inc. (PSG). The transaction closed on June 20, 2025.
Fujirebio is a global R&D-driven company constantly developing new in vitro diagnostics (IVD) testing technologies and unique biomarkers with high clinical value. Its global teams in Japan, the rest of Asia, Europe, and the U.S. focus on delivering products of the highest quality standards to its customers and partners. Fujirebio values contract development and manufacturing organization (CDMO) partnerships with many of the world’s leading diagnostic companies, sharing knowledge, capabilities, and critical materials to supply, develop, or manufacture diagnostic solutions on a wide variety of platforms.
Founded in 2004, PSG specializes in the collection, screening, and supply of high-quality and rare biological materials required for R&D and manufacturing in the IVD and life science industries. PSG is particularly well-positioned in the field of rare diseases. From its state-of-the-art, FDA-registered, ISO-certified facility in Moorestown, New Jersey, the U.S., it provides sera and other samples as materials for control reagents and calibrators for a wide range of diseases and offers sample collection services globally.
Through this acquisition, Fujirebio expects to generate synergies by combining its offering of rare samples and biological materials, further reinforcing its position in the market as a trusted CDMO partner.
Houlihan Lokey originated this transaction and served as the exclusive financial advisor to Fujirebio. This deal represents another successful transaction for Houlihan Lokey in the healthcare sector and highlights the firm’s excellence in cross-border execution in the U.S. and Japan.